We are grateful for external funding from The Research Council of Norway, Norwegian Cancer Society, South-Eastern Norway Regional Health Authority and EU.
Jadhav SS, Luboshits G, Bogen B, Firer MA(2023) Tracking the cellular immune response from early premalignancy to active multiple myeloma in a new model Eur J Immunol, e2350627(in press) DOI 10.1002/eji.202350627, PubMed 37872778
Westhrin M, Blazevski J, Textor A, Abdollahi P, Gopalakrishnan RP, Ngo LT, Hofgaard PO, Heinzelbecker J, Bobic S, Fossum E, Spång HCL, Braathen R, Bogen B(2023) Id-neoantigen vaccine induces therapeutic CD8+ T cells against multiple myeloma: H chain-loss escapees cause FLC MM J Immunother Cancer, 11(8) DOI 10.1136/jitc-2023-006944, PubMed 37607769
Métivier C, Le Saëc P, Gaschet J, Chauvet C, Marionneau-Lambot S, Hofgaard PO, Bogen B, Pineau J, Le Bris N, Tripier R, Alliot C, Haddad F, Chérel M, Chouin N, Faivre-Chauvet A, Rbah-Vidal L(2023) Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma Pharmaceutics, 15(7) DOI 10.3390/pharmaceutics15071817, PubMed 37514004